



Pharmaceuticals Limited

**Registered & Corporate Office :**

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,  
Opp. SBI Executive Enclave, Banjara Hills,

Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

Date: 12<sup>th</sup> February, 2025

To,  
The Manager,  
Corporate Filings Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai- 400 001

The Manager,  
Listing Compliance Department,  
National Stock Exchange of India Ltd.  
Exchange Plaza, Plot no. C/1, G Block,  
Bandra-Kurla Complex, Bandra (E),  
Mumbai - 400 051.

**Security Code: 532815**

**Symbol: SMSPHARMA**

Dear Sir/Madam,

**Subject: Integrated Filing (Financial) for the quarter and nine-months period ended  
December 31, 2024**

Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, read with BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we are submitting herewith the Integrated Filing (Financial) for the quarter and nine-months period ended December 31, 2024.

This will also be hosted on the Company's website, at <https://smspharma.com>

Please take the above intimation on your records.

Thanking you  
Yours faithfully

**For SMS Pharmaceuticals Limited**

**Thirumalesh Tumma  
Company Secretary**

## SMS PHARMACEUTICALS LIMITED

(CIN : L24239TG1987PLC008066)


Regd. Office: Plot No.72, H.No.8-2-334/3&amp;4, Road No.5, Opp.SBI Executive Enclave, Banjara Hills, Hyderabad-500 034, Telangana, India

Tel: +91-40-35359999 / 2525 9999, Fax :+91-40-2525 9889 ; Email : info@smspharma.com

## Statement of Standalone Un-Audited Financial Results for the Quarter and Nine Months Ended 31st December, 2024

(Rs. In Lakhs)


S.No	Particulars	Quarter Ended			Nine Months Ended		Year ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	17,335.33	19,674.79	16,148.22	53,455.26	46,346.51	70,926.34
2	Other Income	212.81	130.46	149.08	480.03	281.40	445.97
3	<b>Total Revenue</b>	<b>17,548.14</b>	<b>19,805.25</b>	<b>16,297.30</b>	<b>53,935.29</b>	<b>46,627.91</b>	<b>71,372.31</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	11,822.32	15,837.66	13,259.89	38,388.77	32,743.96	42,504.00
	(b) Changes in Inventories	(3,283.06)	(4,307.67)	(4,122.12)	(9,518.51)	(6,422.49)	(100.00)
	(c) Manufacturing Expenses	2,075.68	2,199.08	1,948.05	6,094.24	5,158.94	7,344.30
	(d) Employee Benefits Expense	1,864.49	1,792.55	1,501.25	5,345.43	4,402.76	6,414.97
	(e) Finance Cost	420.30	460.58	595.27	1,347.59	1,784.76	2,345.68
	(f) Depreciation and Amortization Expense	869.56	862.03	800.85	2,569.74	2,359.94	3,151.57
	(g) Other Expenses	1,525.65	967.00	673.32	3,282.42	2,127.58	3,078.62
	<b>Total Expenses - (a to g)</b>	<b>15,294.94</b>	<b>17,811.23</b>	<b>14,656.51</b>	<b>47,509.68</b>	<b>42,155.45</b>	<b>64,739.14</b>
5	<b>Profit Before Exceptional Items and Tax (3-4)</b>	<b>2,253.20</b>	<b>1,994.02</b>	<b>1,640.79</b>	<b>6,425.61</b>	<b>4,472.46</b>	<b>6,633.17</b>
6	Exceptional items	-	-	-	-	-	-
7	<b>Profit Before Tax (5-6)</b>	<b>2,253.20</b>	<b>1,994.02</b>	<b>1,640.79</b>	<b>6,425.61</b>	<b>4,472.46</b>	<b>6,633.17</b>
8	Tax Expenses						
	(a) Current Tax relating to Current Period/Year	525.00	470.00	400.00	1,525.00	1,050.00	1,500.00
	(b) Current Tax relating to Earlier Period/Year	(25.94)	-	(0.22)	(25.94)	(0.22)	12.79
	(c) Deferred Tax	36.91	98.20	23.73	150.67	72.38	177.89
		<b>535.97</b>	<b>568.20</b>	<b>423.51</b>	<b>1,649.73</b>	<b>1,122.16</b>	<b>1,690.68</b>
9	<b>Net Profit / (Loss) for the Period/Year (7-8)</b>	<b>1,717.23</b>	<b>1,425.82</b>	<b>1,217.28</b>	<b>4,775.88</b>	<b>3,350.30</b>	<b>4,942.49</b>
10	Other Comprehensive Income (OCI):						
	Items that will not be reclassified to profit or Loss:	2.02	5.99	(8.91)	6.08	(24.68)	7.04
	Income Tax effect on the above	(0.51)	(1.51)	2.24	(1.53)	6.21	(1.77)
		<b>1.51</b>	<b>4.48</b>	<b>(6.67)</b>	<b>4.55</b>	<b>(18.47)</b>	<b>5.27</b>
11	<b>Total Comprehensive Income for the Period/Year (9+10)</b>	<b>1,718.74</b>	<b>1,430.30</b>	<b>1,210.61</b>	<b>4,780.43</b>	<b>3,331.83</b>	<b>4,947.76</b>
12	Earning Per Equity Share of Re.1/- each	2.03	1.68	1.44	5.64	3.96	5.84
	Basic / Diluted (not annualised)						
	Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52	846.52	846.52	846.52	846.52
13	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						56,202.26



**Notes:**

- 1 The above standalone un-audited financial results for the quarter ended December 31, 2024 have been reviewed by the Audit Committee on February 11, 2025 and approved by the Board of Directors at their meeting held on February 12, 2025. The statutory auditors of the Company have carried out a limited review on standalone financial results for the quarter ended December 31, 2024 and expressed an unmodified conclusion thereon.
- 2 These standalone financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ("IND AS") and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 The Company is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 4 During the Quarter, the company has incorporated a subsidiary company namely "SMS Peptides Private Limited " on November 1, 2024 and there were no operations during the reporting period. Hence, it is not considered for consolidation.
- 5 Figures for the previous period have been reclassified/ regrouped wherever necessary to confirm to current period's classification.

Place: Hyderabad  
Date: 12 February, 2025



**For SMS Pharmaceuticals Limited**

A handwritten signature in blue ink, appearing to read "Ramesh Babu Potluri".

**Ramesh Babu Potluri**  
Chairman and Managing Director  
DIN : 00166381






**Independent Auditor's Review Report on the Quarterly Unaudited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To  
The Board of Directors  
SMS Pharmaceuticals Limited  
Hyderabad.

1. We have reviewed the accompanying statement of unaudited financial results of SMS Pharmaceuticals Limited ("the Company"), for the quarter and nine months ended 31<sup>st</sup> December 2024 ('the statement), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. This statement which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" Ind AS 34", prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by Independent Auditor of Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited, primarily to inquiries of company personnel responsible for financial and accounting matters, and applying analytical and other review procedures to financial data and thus provide less assurance than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



4. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results has not been prepared in all material aspects in accordance with the aforesaid Indian Accounting standards and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Hyderabad  
Date: 12.02.2025



For Suryanarayana & Suresh.,  
Chartered Accountants  
Reg. No.006631S

*Muktha Prabhakar*

Muktha Prabhakar  
Partner  
M.No. 200247

UDIN: 25200247BMUJJM4300



**SMS PHARMACEUTICALS LIMITED**

(CIN : L24239TG1987PLC008066)


Regd. Office: Plot No.72, H.No.8-2-334/3&4, Road No.5, Opp.SBI Executive Enclave, Banjara Hills, Hyderabad-500 034, Telangana, India

Tel: +91-40-35359999 / 2525 9999, Fax :+91-40-2525 9889 ; Email : info@smspharma.com

**Statement of Consolidated Un-Audited Financial Results for the Quarter and Nine months Ended 31st December, 2024**

(Rs. In Lakhs )

S.No	Particulars	Quarter Ended			Nine months Ended		Year ended
		31.12.2024	30.09.2024	31.12.2023	31.12.2024	31.12.2023	31.03.2024
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue From Operations	17,335.33	19,674.79	16,148.22	53,455.26	46,346.51	70,926.34
2	Other Income	212.81	130.46	149.08	480.03	281.40	445.97
3	<b>Total Revenue</b>	<b>17,548.14</b>	<b>19,805.25</b>	<b>16,297.30</b>	<b>53,935.29</b>	<b>46,627.91</b>	<b>71,372.31</b>
4	<b>Expenses</b>						
	(a) Cost of Materials Consumed	11,831.64	15,877.32	13,247.98	38,433.12	32,779.51	42,526.49
	(b) Changes in Inventories	(3,283.06)	(4,307.67)	(4,122.12)	(9,518.51)	(6,422.49)	(100.00)
	(c) Manufacturing Expenses	2,075.68	2,199.08	1,948.05	6,094.24	5,158.94	7,344.30
	(d) Employee Benefits Expense	1,864.49	1,792.55	1,501.25	5,345.43	4,402.76	6,414.97
	(e) Finance Cost	420.30	460.58	595.27	1,347.59	1,784.76	2,345.68
	(f) Depreciation and Amortization Expense	869.56	862.03	800.85	2,569.74	2,359.94	3,151.57
	(g) Other Expenses	1,525.65	967.00	673.32	3,282.42	2,127.58	3,078.62
	<b>Total Expenses - (a to g)</b>	<b>15,304.26</b>	<b>17,850.89</b>	<b>14,644.60</b>	<b>47,554.03</b>	<b>42,191.00</b>	<b>64,761.63</b>
5	<b>Profit Before Exceptional Items and Tax (3-4)</b>	<b>2,243.88</b>	<b>1,954.36</b>	<b>1,652.70</b>	<b>6,381.26</b>	<b>4,436.91</b>	<b>6,610.68</b>
6	Exceptional items	-	-	-	-	-	-
7	<b>Profit Before Tax (5-6)</b>	<b>2,243.88</b>	<b>1,954.36</b>	<b>1,652.70</b>	<b>6,381.26</b>	<b>4,436.91</b>	<b>6,610.68</b>
8	<b>Tax Expenses</b>						
	(a) Current Tax relating to Current Period/Year	525.00	470.00	400.00	1,525.00	1,050.00	1,500.00
	(b) Current Tax relating to Earlier Period/Year	(25.94)	-	(0.22)	(25.94)	(0.22)	12.79
	(c) Deferred Tax	36.91	98.20	23.73	150.67	72.38	177.89
		535.97	568.20	423.51	1,649.73	1,122.16	1,690.68
9	<b>Net Profit / (Loss) for the Period/Year (7-8)</b>	<b>1,707.91</b>	<b>1,386.16</b>	<b>1,229.19</b>	<b>4,731.53</b>	<b>3,314.75</b>	<b>4,920.00</b>
10	Share of Profit/(loss) in associate company, net of tax	116.26	23.75	(81.16)	150.49	(60.04)	62.60
11	<b>Net Profit / (Loss) after taxes and share of profit/(loss) from associate(9+10)</b>	<b>1,824.17</b>	<b>1,409.91</b>	<b>1,148.03</b>	<b>4,882.02</b>	<b>3,254.71</b>	<b>4,982.60</b>
12	Other Comprehensive Income (OCI):						
	(i) Items that will not be reclassified to profit or Loss:	2.02	5.99	(8.91)	6.08	(24.68)	7.04
	(ii) Income Tax effect on the above	(0.51)	(1.51)	2.24	(1.53)	6.21	(1.77)
	(iii) Share of other comprehensive income in Associate	0.53	0.53	1.39	1.57	4.14	1.99
	(iv) Share of Income Tax effect on the above in Associate	(0.14)	(0.14)	(0.36)	(0.41)	(1.08)	(0.52)
		1.90	4.87	(5.64)	5.71	(15.41)	6.74
13	<b>Total Comprehensive Income for the Period/Year (11+12)</b>	<b>1,826.07</b>	<b>1,414.78</b>	<b>1,142.39</b>	<b>4,887.73</b>	<b>3,239.30</b>	<b>4,989.34</b>
14	Earning Per Equity Share of Re.1/- each Basic / Diluted (not annualised)	2.15	1.67	1.36	5.77	3.84	5.89
	Paid-up equity share capital (Face Value of Re.1/- each)	846.52	846.52	846.52	846.52	846.52	846.52
15	Reserves excluding Revaluation Reserve as per balance sheet of previous accounting year						52,786.37



**Notes:**

- 1 The above Consolidated un-audited financial results for the quarter ended December 31, 2024 have been reviewed by the Audit Committee on February 11, 2025 and approved by the Board of Directors at their meeting held on February 12, 2025. The statutory auditors of the Company have carried out a limited review on standalone financial results for the quarter ended December 31, 2024 and expressed an unmodified conclusion thereon.
- 2 These consolidated financial results of the Company have been prepared in accordance with the Indian Accounting Standards prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder ('IND AS') and other accounting principles generally accepted in India and guidelines issued by the Securities and Exchange Board of India ("SEBI"). (Listing Obligations and Disclosure Requirements) Regulations, 2015.
- 3 VKT Pharma Private Limited is considered as an Associate Company for the consolidation in which the company holds 34.83% as on December 31, 2024 in their equity. Accordingly the results include appropriate share of the results of the said Associate.
- 4 The Company has joint venture namely "Chemo SMS Enterprises SL" and also during the reporting period, the company incorporated subsidiary namely "SMS Peptides Private Ltd " on November 1, 2024 where there are no operations for these entities during the reporting period. Hence, both the entities are not considered for consolidation.
- 5 Consolidated Financial Statements have been prepared by applying Accounting Standard "Ind AS 28 "Investments in Associates and Joint Ventures" as applicable under the Companies Act, 2013 and applicable rules there under.
- 6 The Group is engaged in the manufacturing of Active Pharmaceutical Ingredients and their intermediates and the same constitutes a single reportable business segment as per Ind AS108.
- 7 Figures for the previous period have been reclassified/ regrouped wherever necessary to confirm to current period's classification.

Place: Hyderabad  
Date: 12 February, 2025




**For SMS Pharmaceuticals Limited**

A handwritten signature in blue ink, appearing to read "Ramesh Babu Potluri".

**Ramesh Babu Potluri**  
Chairman and Managing Director  
DIN : 00166381





**Independent Auditor's Review Report on the Quarterly Unaudited Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended**

To  
The Board of Directors  
SMS Pharmaceuticals Limited  
Hyderabad.

1. We have reviewed the accompanying Statement of Consolidated Unaudited financial results of M/s SMS Pharmaceuticals Limited("the holding Company") and its share of the net profit after tax and other comprehensive income of its associate (the holding company and its associate hereinafter referred to as "the Group"), for the quarter and nine months ended December 31, 2024 ("the Statement"). The Statement is being submitted by the holding company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations, 2015").
2. This Statement, which is the responsibility of the holding company's management and has been approved by the holding company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Consolidated Statement is free of material misstatement. A review is limited, primarily to inquiries of company personnel responsible for financial and accounting matters, and applying analytical and other review procedures to financial data and thus provide less assurance than an audit conducted in accordance with Standard on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.





4. We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.
5. The Statement includes the results of the following entities:
  - a) M/s VKT Pharma Private Limited
  - b) M/s Chemo SMS Enterprises SL
  - c) M/s. SMS Peptides private Ltd
6. Based on our review conducted and procedures performed as stated in paragraph 3 above and based on the consideration of the review reports of the other auditor referred to in paragraph 7, nothing has come to our attention that causes us to believe that the accompanying Statement has not been prepared in all material respects in accordance with the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India and has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
7. The consolidated unaudited financial results includes the holding company's share of profit after tax of Rs.116.26 Lakhs and Rs.150.49 Lakhs for the quarter and nine months ended December 31, 2024 respectively and other comprehensive income of Rs.0.39 Lakhs and Rs.1.16 Lakhs for the quarter and nine months ended December 31, 2024 respectively as considered in the statement, in respect of the associate namely M/s VKT Pharma Private Limited which have been reviewed by their auditor.
8. The consolidated financial results also includes the unaudited financial results of joint venture namely M/s Chemo SMS Enterprises SL in which there is no operations during the quarter ended December 31, 2024. Hence, there is no significant effect on the financial statements and not material to the group.
9. During the reporting period, the holding company has incorporated a subsidiary company namely "SMS Peptides Private Ltd" on November 1, 2024 and there were no operations during the reporting period. Hence, it is not considered for Consolidation.
10. Our conclusion on the Statement is not modified in respect of the above paragraphs 8 and 9.

Place: Hyderabad  
Date: 12.02.2025

For Suryanarayana & Suresh.,  
Chartered Accountants  
Reg. No.006631S



*Muktha Prabhakar*

Muktha Prabhakar  
Partner  
M. No. 200247

UDIN: 25200247BMUJJN2732



Pharmaceuticals Limited

**Registered & Corporate Office :**

Plot No. 72, H. No. 8-2-334/3 & 4, Road No. 5,

Opp. SBI Executive Enclave, Banjara Hills,

Hyderabad - 500 034, Telangana, INDIA.

Tel : +91-40-2525 9999, Fax : +91-40-2525 9889

CIN : L24239TG1987PLC008066

Email: info@smspharma.com, www.smspharma.com

- B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.: Annexure-B, No deviation
  
- C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES: Not Applicable
  
- D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half yearly filings i.e., 2nd and 4th quarter) : Not Applicable for this quarter.
  
- E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG WITH ANNUAL AUDITED FINANCIAL RESULTS: (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter) – Not Applicable for this quarter



Statement of Deviation / Variation in utilisation of funds raised through Preferential Allotment

<b>Name of listed entity</b>	SMS Pharmaceuticals Limited					
<b>Mode of Fund Raising</b>	Preferential Issue					
<b>Date of Raising Funds</b>	19 <sup>th</sup> March, 2024 (Allotment of 90,00,000 convertible warrants upon receipt of 25% of the issue price at Rs.127/- per warrant)					
<b>Amount Raised</b>	Rs. 28,57,50,000/-					
<b>Report filed for Quarter ended</b>	31 <sup>st</sup> December, 2024					
<b>Monitoring Agency</b>	Applicable					
<b>Monitoring Agency Name, if applicable</b>	M/s. CARE Ratings Limited					
<b>Is there a Deviation / Variation in use of funds raised</b>	No					
<b>If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders</b>	Not Applicable					
<b>If Yes, Date of shareholder Approval</b>	Not Applicable					
<b>Explanation for the Deviation / Variation</b>	Not Applicable					
<b>Comments of the Audit Committee after review</b>	Nil					
<b>Comments of the auditors, if any</b>	Nil					
<b>Objects for which funds have been raised and where there has been a deviation, in the following table</b>						
<b>Original Object</b>	<b>Modified Object, if any</b>	<b>Original Allocation</b>	<b>Modified allocation, if any</b>	<b>Funds Utilised till 31<sup>st</sup> December, 2024</b>	<b>Amount of Deviation/Variation for the quarter according to applicable object</b>	<b>Remarks if any</b>
The proceeds of the Preferential issue shall be utilized to meet the Capital Expenditure requirement for Expansion of production capacities in phased manner and installation of additional utility equipment's as well as recovery systems. Proposed to start backward integration of Key Starting Materials (KSM) for existing as well as new products under pipeline at R&D by setting up new production blocks. Further, it may be utilized to meet Working Capital Requirement and General Purpose also.	Not Applicable	Rs. 28,57,50,000/-	Not Applicable	Rs. 28,57,00,000/-	NIL	-




Deviation or variation could mean:

- (a) Deviation in the objects or purposes for which the funds have been raised or
- (b) Deviation in the amount of funds actually utilized as against what was originally disclosed or
- (c) Change in terms of a contract referred to in the fund raising document i.e. prospectus, letter of offer, etc.

For SMS Pharmaceuticals Limited

  
Lakshmi Narayana Tammineedi  
Chief Financial Officer



Place: Hyderabad

Date: 12.02.2025